Investigational Drug Information for JNJ-53718678
✉ Email this page to a colleague
What is the drug development status for JNJ-53718678?
JNJ-53718678 is an investigational drug.
There have been 17 clinical trials for JNJ-53718678.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 6th 2021.
The most common disease conditions in clinical trials are Virus Diseases, Infections, and Infection. The leading clinical trial sponsors are Janssen Research & Development, LLC, Janssen Sciences Ireland UC, and [disabled in preview].
Summary for JNJ-53718678
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 10 |
| WIPO Patent Applications | 8 |
| Japanese Patent Applications | 2 |
| Clinical Trial Progress | Phase 2 (2021-09-06) |
| Vendors | 36 |
Recent Clinical Trials for JNJ-53718678
| Title | Sponsor | Phase |
|---|---|---|
| A Study in Healthy Adult Participants to Assess the Effects of Ciclosporin Administration on Rilematovir | Janssen Research & Development, LLC | Phase 1 |
| A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection | Janssen Research & Development, LLC | Phase 2 |
| A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV) | Janssen Research & Development, LLC | Phase 3 |
Clinical Trial Summary for JNJ-53718678
Top disease conditions for JNJ-53718678
Top clinical trial sponsors for JNJ-53718678
US Patents for JNJ-53718678
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
